Platelet activation in patients with the Raynaud phenomenon

Internal Medicine Journal

Volumn 42, Issue 5, 2012, Pages 531-535

  Polidoro, L ^a   Barnabei, R ^b   Giorgini, P ^a   Petrazzi, L ^a   Ferri, C ^a   Properzi, G ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

8 Epi prostaglandin F2 ; GpIIb IIIa; PAC 1; Platelet; The Raynaud phenomenon; Tromboxane A2

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; DUAL SPECIFICITY PHOSPHATASE 2; THROMBOXANE A2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; OXIDATIVE STRESS; PRIMARY RAYNAUD PHENOMENON; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; RECEPTOR DOWN REGULATION; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RAYNAUD DISEASE; YOUNG ADULT;

EID: 84861430085     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02399.x     Document Type: Article

References (25)

1. Sunderkotter C. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology 2008; 47: 234-5.
2. Harrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005; 44: 587-96.
3. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Venodilatation in Raynaud's disease. Lancet 1993; 342: 1451-4.
4. Kaheleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995; 38: 1-4.
5. Lau CS, McLauren M, Saniabaldi A, Belch JJF. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993; 22: 97-101.
6. Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F etal. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001; 30: 290-6.
7. Ikehata K, Kawauchi S, Kohno F, Nishiyama M, Ide N. Increased platelet function and von Willebrand factor in vibration syndrome. Exp Med 1980; 27: 23-8.
8. Turton EPL, Kent PJ, Kester RC. The aetiology of Raynaud's phenomenon. Cardiovasc Surg 1998; 6: 431-40.
9. Biondi ML, Marasini B. Abnormal platelet aggregation in patients with Raynaud's phenomenon. Clin Pathol 1989; 42: 716-18.
10. Hutton RA, Mikhailidis DP, Bernstein RM etal. Assessment of platelet function in patients wiyh Raynaud's syndrome. Clin Pathol 1984; 37: 182-7.
11. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993; 28: 78-85.
12. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 4-8.
13. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MIV. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21: 1477-83.
14. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res 2001; 38: 93-103.
15. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146-50.
16. Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Hunt M, Stanke-Labesque F etal. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum 2001; 44: 1143-8.
17. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R etal. The F2-isoprostane 8 epi-prostaglandin F2 increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 1998; 18: 1248-56.
18. Davì G, Patrono C. Platelets activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
19. Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 1932; 183: 187-92.
20. LeRoy EC, Medger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-8.
21. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
22. Shattil SJ, Hoxie LA, Cunningham MC, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-14.
23. Rásó E, Tóvári J, Ladányi A, Varga N, Tímár J. Ligand-Mimetic anti- αIIbβ3 Antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells. Pathol Oncol Res 2005; 11(Suppl 4): 218-23.
24. Jeremy JY, Mikhailidis DP, Hutton RA, Dandona P. The effect of cooling on in vitro vascular prostacyclin and platelet thromboxane A2 synthesis: relevance to cold-induced pathology. Microcirc Endothelium Lymphatics 1988; 4: 3-20.
25. Bakst R. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol 2008; 59: 633-53.